Solosorb (Gel) Instructions for Use
Marketing Authorization Holder
Grotex, LLC (Russia)
ATC Code
A07B (Intestinal adsorbents)
Active Substance
Polymethylsiloxane polyhydrate (Grouping name)
Dosage Form
| Solosorb | Gel for oral suspension: tubes 225 g |
Dosage Form, Packaging, and Composition
Gel for the preparation of an oral suspension in the form of a moist mass of white or almost white color, consisting of jelly-like lumps of various sizes, odorless.
| 1 tube | |
| Polymethylsiloxane polyhydrate | 225 g |
225 g – tubes – cardboard packs.
Clinical-Pharmacological Group
Enterosorbent
Pharmacotherapeutic Group
Enterosorbent agent
Pharmacological Action
Enterosorbing agent.
Polymethylsiloxane has a porous structure of an organosilicon matrix (molecular sponge) of a hydrophobic nature, which is characterized by a sorption action only towards medium-molecular-weight toxic metabolites (molecular weight from 70 to 1000).
Polymethylsiloxane has pronounced sorption and detoxification properties. In the lumen of the gastrointestinal tract, it binds and removes from the body endogenous and exogenous toxic substances of various natures, including bacteria and bacterial toxins, antigens, food allergens, medicinal products and poisons, salts of heavy metals, radionuclides, alcohol; it also sorbs some products of the body’s metabolism, including excess bilirubin, urea, cholesterol and lipid complexes, as well as metabolites responsible for the development of endogenous toxicosis.
Polymethylsiloxane does not reduce the absorption of vitamins and microelements, contributes to the restoration of disturbed intestinal microflora and does not affect its motor function.
Pharmacokinetics
Not absorbed in the gastrointestinal tract, excreted unchanged within 12 hours.
Indications
In adults and children as a detoxification agent: acute and chronic intoxications of various origins; acute poisonings with potent and poisonous substances, including medicinal products and alcohol, alkaloids, salts of heavy metals; acute intestinal infections of any genesis as part of complex therapy (foodborne toxic infections, salmonellosis, dysentery, diarrheal syndrome of non-infectious origin, dysbiosis); purulent-septic diseases accompanied by severe intoxication, as part of complex therapy; food and drug allergy; hyperbilirubinemia (viral hepatitis) and hyperazotemia (chronic renal failure); for the prevention of chronic intoxications in workers of hazardous industries (occupational intoxications with chemical agents of polytropic action, xenobiotics, incorporated radionuclides, lead, mercury, arsenic compounds, petroleum products, organic solvents, nitrogen oxides, carbon, fluorides, salts of heavy metals).
ICD codes
| ICD-10 code | Indication |
| A02 | Other salmonella infections |
| A03 | Shigellosis |
| A04 | Other bacterial intestinal infections |
| A05 | Other bacterial food poisonings, not elsewhere classified |
| A09.0 | Other and unspecified gastroenteritis and colitis of infectious origin (infectious diarrhea NOS) |
| A40 | Streptococcal sepsis |
| A41 | Other sepsis |
| B15 | Acute hepatitis A |
| B16 | Acute hepatitis B |
| B17 | Other acute viral hepatitis |
| B18 | Chronic viral hepatitis |
| E80.6 | Other disorders of bilirubin metabolism |
| F10.0 | Mental and behavioral disorders due to alcohol use – acute intoxication |
| F11.0 | Mental and behavioral disorders due to opioid use – acute intoxication |
| F13.0 | Mental and behavioral disorders due to use of sedatives and hypnotics – acute intoxication |
| K59.1 | Functional diarrhea |
| K63.8 | Other specified diseases of intestine |
| N18 | Chronic kidney disease |
| R54 | Acute intoxication |
| R79.8 | Other specified abnormal findings of blood chemistry |
| T50.9 | Other and unspecified drugs, medicaments and biological substances |
| T51 | Toxic effect of alcohol |
| T52 | Toxic effect of organic solvents |
| T56 | Toxic effect of metals |
| T57 | Toxic effect of other inorganic substances |
| T58 | Toxic effect of carbon monoxide |
| T59 | Toxic effect of other gases, fumes, and vapors |
| T65 | Toxic effect of other and unspecified substances |
| T78.1 | Other adverse food reactions, not elsewhere classified |
| T88.7 | Unspecified adverse effect of drug or medicament |
| Z57 | Occupational exposure to risk factors |
| ICD-11 code | Indication |
| 1A01 | Intestinal infection caused by other Vibrio species |
| 1A02 | Intestinal infections due to Shigella |
| 1A03.Z | Intestinal infections caused by Escherichia coli, unspecified |
| 1A09.Z | Salmonella infection, unspecified |
| 1A0Z | Bacterial intestinal infections, unspecified |
| 1A1Z | Bacterial foodborne intoxications, unspecified |
| 1A40.Z | Infectious gastroenteritis or colitis, unspecified |
| 1E50.0 | Acute hepatitis A |
| 1E50.1 | Acute hepatitis B |
| 1E50.Z | Acute viral hepatitis, unspecified |
| 1E51.Z | Chronic viral hepatitis, unspecified |
| 1G40 | Sepsis without septic shock |
| 4A85.21 | Urticaria or angioedema caused by food |
| 4A85.2Z | Food hypersensitivity, unspecified |
| 5C58.02 | Dubin-Johnson syndrome |
| 5C58.0Y | Other specified disorders of bilirubin metabolism or excretion |
| 5C90.1 | Liver diseases due to disorders of porphyrin or bilirubin metabolism or transport |
| 6C40.3 | Alcohol intoxication (inebriation) |
| 6C43.3 | Opioid intoxication |
| 6C44.3 | Intoxication due to sedatives, hypnotics or anxiolytics |
| DA92.1 | Pneumatosis intestinalis of the small intestine |
| DA98.Z | Polyps of small intestine, unspecified |
| DB31.1 | Pneumatosis of the colon |
| DB36.Z | Certain infections of the colon, unspecified |
| DD91.2 | Functional diarrhea |
| DD93.Y | Other specified functional gastrointestinal disorders in infants, toddlers and school-age children |
| DD9Z | Functional gastrointestinal disorders, unspecified |
| DE2Z | Diseases of the digestive system, unspecified |
| GB61.Z | Chronic kidney disease, unspecified stage |
| MA18.Z | Abnormalities of blood chemistry, unspecified |
| MG2A | Frailty syndrome |
| NE60 | Poisoning by drugs, medicaments or biological substances, not elsewhere classified |
| NE61 | Toxic effect of poisonous substances, chiefly nonmedicinal, not elsewhere classified |
| NE6Z | Harmful effect of unspecified substance |
| NF09 | Adverse effects, not elsewhere classified |
| QD84.Z | Exposure to occupational risk factors, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally, maintaining an interval of 1-2 hours before or after meals or intake of any other medicinal products.
For adults, the dose is 15 g to 22.5 g (approximately one to one and a half tablespoons), taken three times daily.
For children aged 3 to 5 years, the dose is 7.5 g (approximately half a tablespoon), taken three times daily.
For children aged 1 to 3 years, the dose is 5 g (approximately one teaspoon), taken three times daily.
For infants up to 1 year, administer 2.5 g (approximately half a teaspoon). Mix the gel thoroughly with a triple volume of breast milk, infant formula, or water. Give this mixture before each feeding (typically six times daily).
In cases of severe intoxication, the dosage for adults may be doubled during the first three days of therapy, under medical supervision.
The average duration of treatment is 3 to 5 days for acute conditions. For chronic intoxications and allergic diseases, the course can be extended to 2-3 weeks, as directed by a physician.
For prophylactic use in occupational hazards, take the standard adult dose once or twice daily.
Adverse Reactions
From the digestive system nausea, constipation.
Contraindications
Intestinal atony.
Use in Pregnancy and Lactation
Not contraindicated during pregnancy and breastfeeding.
Pediatric Use
The drug is approved for use in children and adolescents under 18 years of age.
Special Precautions
Can be used in complex therapy with other medicinal products, provided the rule of separate administration in time is observed: 1-2 hours before or after taking other medicinal products.
Drug Interactions
When taken simultaneously, a decrease in the absorption of other medicinal products is possible.
Storage Conditions
Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer